肺腺癌组织中Nanog表达与化疗疗效及预后的关系

doi:10.3969/j.issn.1671-7171.2016.12.024

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1845 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the expression of Nanog in cancer tissue before chemotherapy in advanced lung adenocarcinoma and its influence on the chemotherapeutic effect and prognosis.【Methods】 Pathological data of fifty-six advanced lung adenocarcinoma cases confirmed by histopathology between January 2010 and December 2013 in our hospital was collected. All patients completed at least four cycles of pemetrexed chemotherapy combined with cisplatin. The expression of Nanog was detected by immunohistochemistry in all cancer tissues.【Results】 High expression of Nanog protein in cancer tissue occurred in 29 cases (51.8%) out of 56 cases of advanced lung adenocarcinoma, low expression in 27 cases (48.2%); There was no correlation between the expression level and the gender of the patients (P=0.643), age (P=0.143) and clinical stage (P=0.096); the efficiency of chemotherapy (24.1%) in the Nanog high expression group was lower than that of the low expression group (70.4%), the difference was statistically significant (P<0.05). Univariate analysis showed that clinical stage and Nanog expression levels were associated with clinical prognosis in patients with lung adenocarcinoma (P mean <0.05); Multivariate analysis showed that Nanog expression was an independent prognostic factor in patients with lung adenocarcinoma (P<0.05).【Conclusion】 Nanog high expression may indicate a poor response to pemetrexed chemotherapy combined with cisplatin in patients with lung adenocarcinoma, and even a worse clinical outcome.

Key words： Lung Neoplasms/DT Adenocarcinoma/DT Antineoplastic Agents/TU Prognosis

Received: 19 October 2015

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAO Su-mei
	HE Hai-yan
	CHEN Jin-liang
	et al

Cite this article:

YAO Su-mei,HE Hai-yan,CHEN Jin-liang, et al. Correlations of Nanog Expression in Lung Adenocarcinoma Tissue with Chemotherapy Response and Prognosis[J]. JOURNAL OF CLINICAL RESEARCH, 2016, 33(12): 2364-2368.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2016.12.024 OR http://www.jcr.net.cn/EN/Y2016/V33/I12/2364

[1] Lortet-Tieulent J, Soerjomataram I, Ferlay J,et al.International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women[J].Lung Cancer,2014, 84(1): 13-22.
[2] Chen W, Zheng R, Zhang S,et al. The incidences and mortalities of major cancers in China, 2009[J].Chin J Cancer(Engl),2013, 32(3): 106-112.
[3] Chilosi M, Murer B. Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy[J].Arch Pathol Lab Med,2010, 134(1): 55-65.
[4] Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells[J].Cell,2003, 113(5): 643-655.
[5] Pan G, Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency[J].Cell Res,2007, 17(1): 42-49.
[6] Wang D, Lu P, Zhang H, et al. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients[J].Oncotarget,2014,5(21):10803-10815.
[7] 熊靓,孙庭. 胚胎干细胞基因Nanog,Oct-4基因在前列腺癌中的表达及意义及意义[J].医学临床研究, 2011,28(7):1239-1241.
[8] 孙向东,宗晓福,汪栋. 采用组织芯片研究非小细胞肺癌中Oct-4、Nanog基因的表达意义[J].临床和实验医学杂志, 2012,18(16):1258-1260.
[9] 杨旭,许光,雷振,等. RECIST 1.1与WHO、RECIST 1.0标准评价周边型肺癌疗效比较[J].中国医学影像学杂志, 2012,5(10):355-358.
[10] Huntly BJ,Gilliland DG. Cancer biology:summing up cancer stem cells[J].Nature,2005,435(7046):1169-1170.
[11] Wu X, Chen H, Wang X. Can lung cancer stem cells be targeted for therapies[J].Cancer Treat Rev,2012, 38(6): 580-588.
[12] Li L, Yu H, Wang X, et al. Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy[J].J Exp Clin Cancer Res,2013,32:28.
[13] Nirasawa S, Kobayashi D, Tsuji N, et al. Watanabe N. Diagnostic relevance of overexpressed Nanog gene in early lung cancers[J].Oncol Rep,2009, 22(3):587-591.
[14] Di J, Duiveman-de Boer T, Zusterzeel PL, et al. The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients[J].Cell Oncol,2013,36(5):363-374.
[15] Schulenburg A, Ulrich-Pur H, Thurnher D, et al. Neoplastic stem cells: a novel therapeutic target in clinical oncology[J].Cancer,2006, 107(10): 2512-2520.
[16] Bourguignon L, Peyrollier K, Xia W,et al. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and Ankyrin-regulated multidrug efflux in breast and ovarian tumor cells[J].J Biol Chem,2008, 283(25):17635-17651.
[17] Jeter CR, Badeaux M, Choy G, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development[J].Stem Cells,2009, 27(5):993-1005.